Generic Name and Formulations:
Metronidazole 1.3%; vaginal gel; contains parabens.
Indications for NUVESSA:
Bacterial vaginosis in non-pregnant women.
One applicatorful once daily at bedtime.
<18yrs: not established.
Concomitant or within 2 weeks of disulfiram use. Concomitant alcohol and preparations containing ethanol or propylene glycol during and for ≥24hrs after treatment.
Not for ophthalmic, dermal, or oral use. CNS diseases. Pregnancy (Cat.B). Nursing mothers: not recommended (may pump/discard milk during and for 24hrs after therapy ends).
See Contraindications. May potentiate oral anticoagulants, lithium. May be potentiated by cimetidine. May interfere with serum chemistry tests.
Vulvovaginal candidiasis, headache, vulvovaginal pruritus, nausea, diarrhea, dysmenorrhea.
Gel—5g (w. applicator)
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Weight Gain After Quitting Smoking May Increase Risk for T2D
- In Teens, Young Adults, High BMI May Hurt Cardiovascular Health
- Obesity Paradox Affects Type 2 Diabetes Mortality Rates
- Bi-Directional Association Observed Between Obstructive Sleep Apnea and Diabetes
- Real-World Data Show Reduced Fracture Rates in Teriparatide-Treated Osteoporosis